www.InvestorStemCell.com Not an InvestorStemCell member? Sign Up!

Sign Up

Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector.

www.investorstemcell.com

World’s First Approved Stem Cell Drug Approved:Osiris Therapeutics Inc.

World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal Historic decision offers hope to children suffering from life-threatening...

www.investorstemcell.com

BioTime HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells

HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease       05/14 08:45 AM   ALAMEDA, Calif.–(BUSINESS...

imagesCAIMYTW9

Michael Marletta Appointed to Governing Board of California’s Stem Cell Agency

18 May 2012

San Francisco, CA –Michael A. Marletta, PhD, President and CEO of The Scripps Research Institute, has been appointed to the Independent Citizens Oversight Committee (ICOC), the governing board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) “California has led the nation in stem cell research and I’m delighted to be part of an institution that has the potential to change the way we look at and treat disease,” says Dr. Marletta. “Throughout my career my research has focused on the intersection of biology, chemistry and medicine so I hope I will be able to make a valuable contribution to the field of regenerative medicine.” Dr. Marletta, a renowned biochemist, was named to the ICOC by California State Treasurer Bill Lockyer. He takes one of the seats designated for a representative of a California University under Proposition 71, the voter–approved initiative that created the stem cell agency....

Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences

17 May 2012

Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences       05/17 09:00 AM   SAN DIEGO, May 17, 2012 /PRNewswire/ — Cardium Therapeutics (CXM:$0.23,00$-0.005,0-2.13%) today announced that Christopher...

StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial Trial Proceeding to Enroll Patients With Incomplete Injury

17 May 2012

      05/17 09:00 AM   NEWARK, Calif., May 17, 2012 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) today announced completion of the first planned interim safety review of the Company’s Phase I/II spinal cord injury clinical trial,...

Welcome to Investor Stemcell! New to the site? Take a minute and Sign Up Today!